Passionate about making a difference for patients.
San Francisco, CA
Joined March 2011
- Tweets1.2K
- Following655
- Followers693
- Likes2.3K
Marianne De Backer, MSc, PhD, MBA retweeted
Congrats to Foundation Board Member Marianne De Backer (@MDDBacker) on her new appointment!
bit.ly/40jzG7w
Marianne De Backer, MSc, PhD, MBA retweeted
Legendary biotech leader George Scangos, PhD, today announced his retirement after a storied career delivering impactful medicines to patients worldwide. With his support, Vir's BOD unanimously appointed Marianne De Backer, MSc, PhD, MBA, as his successor. bit.ly/3J94z8u
Marianne De Backer, MSc, PhD, MBA retweeted
Mit dieser Haushaltsentscheidung entsteht ein gutes Stück mehr Zukunft für den Standort Deutschland und Hoffnung für viele Patienten überall auf unser Welt.
Der Haushaltsausschuss des Bundestages hat eine Startfinanzierung für das geplante Translationszentrum Gen- und Zelltherapien von @Bayer und @ChariteBerlin auf den Weg gebracht. Ein wichtiges Signal für die #BrainCityBerlin!
ALT Zitat mit Foto der Regierenden Bürgermeisterin: „Das Translationszentrum für Gen- und Zelltherapien ist ein echter Gewinn für Berlin, den Forschungsstandort Deutschland und für Patientinnen und Patienten weltweit, die von den dort entwickelten Therapieansätzen profitieren werden.“
Marianne De Backer, MSc, PhD, MBA retweeted
🆕 @NatureMedicine
Heart manifestations of #LongCovid
A prospective MRI study of 346 people with mild Covid, and controls, demonstrated myocardial inflammation at 3 months, worse w/ symptoms, and edema at ~1 year
by @v_puntmann and colleagues @GoetheCVI
nature.com/articles/s41591-0…
Marianne De Backer, MSc, PhD, MBA retweeted
Proud to announce our newest investment in @ReCodeTx, a company pioneering game-changing #precisionmedicine for underserved patients with #geneticdiseases, like #cysticfibrosis. Learn about their technology: bwnews.pr/3OFKUwq
Marianne De Backer, MSc, PhD, MBA retweeted
We entered into a license agreement with a new joint venture, Visirna Therapeutics, Inc. #Visirna will develop and commercialize four of Arrowhead’s investigational #RNAi therapeutics for #cardiometabolic diseases in Greater China. Learn more here: bit.ly/3KcU5le $ARWR
Marianne De Backer, MSc, PhD, MBA retweeted
The VISTA program is a series of mid to late-stage clinical trials for those with #CardiovascularDiseases. With investigational #RNAi candidate ARO-ANG3, we hope to provide a potential treatment. Learn more about our three ongoing VISTA studies here: bit.ly/3oCGJ7u $ARWR
Marianne De Backer, MSc, PhD, MBA retweeted
Our new commercial manufacturing facility opened last year added 300,000 square feet of capacity, with each of the 9 suites offering up to 2,000L scales. It also houses in-house fill and finish QC labs and warehousing that makes #Viralgen the largest #AAV CDMO worldwide. 🧪🔬
Marianne De Backer, MSc, PhD, MBA retweeted
Happening now at @MilkenInstitute Conference: “How Can We Ensure Access to Innovation for All?” W/@drmeenasesh @MDDBacker @JayasreeKIyer and AmirAli Talasaz of @GuardantHealth. Hosted by Mark McClellan of @DukeMargolis.
Marianne De Backer, MSc, PhD, MBA retweeted
Since joining @Bayer in 2019, industry veteran Marianne De Backer spearheaded the signing of nearly 30 new alliances and made four acquisitions. Recently, @MDDBacker launched a program to promote career development of underrepresented groups. #WILS2021 fiercepharma.com/special-rep…
Marianne De Backer, MSc, PhD, MBA retweeted
And the 2021 Entrepreneur Of The Year® National Overall Award Winner is...Sheila Mikhail of @ask_bio! Congratulations to this incredible entrepreneur who is making a tangible impact in the healthcare of our current and future generations. spr.ly/6019JdSy1 #EOYUS
ALT EOYUS 2021 National Overall Award Winner, Sheila Mikhail of AskBio
Marianne De Backer, MSc, PhD, MBA retweeted
Using Viralgen's optimized platform for AAV manufacturing allows for data-driven decisions at every stage of development, from 2L to 2000L. 📈🔍 #OptimizedManufacturingPlatform
🔗 Learn more about our capabilities at viralgenvc.com/services.
Marianne De Backer, MSc, PhD, MBA retweeted
Congratulations to AskBio's Dr. Jude Samulski and his fellow industry leaders for being named to Endpoints News list of the Top 20 Most Influential R&D Executives: bit.ly/38pP2O8
Marianne De Backer, MSc, PhD, MBA retweeted
Interesting back story here, a race to an M&A deal in 7 weeks --
Bayer nabs star biotech Vividion with a $2B buyout and an ‘arms-length’ pact, pulling a partner out of the IPO conga line
endpts.com/bayer-nabs-star-b…
Marianne De Backer, MSc, PhD, MBA retweeted
Bayer nabs star biotech Vividion with a $2B buyout and an ‘arms-length’ pact, pulling a partner out of the IPO conga line
endpts.com/bayer-nabs-star-b…
Marianne De Backer, MSc, PhD, MBA retweeted
About a month ago has passed since our commercial facility inauguration. An event which was full of surprises, with special guests and with our team, all made very it special! ✨ Check out this short movie with our favorite moments. 🎬 #ViralgenCommercial
vimeo.com/577466549
Marianne De Backer, MSc, PhD, MBA retweeted
We are happy to announce #acquisition of @VividionRx
Vividion is utilizing novel discovery technologies to unlock high-value, traditionally undruggable targets w/ precision therapeutics. #Oncology #Immunology
Learn here more: media.bayer.com/baynews/bayn…
Marianne De Backer, MSc, PhD, MBA retweeted
Viralgen's new commercial facility inauguration was a great success. We are deeply grateful to everyone who made this milestone possible. With all your support, we continue to move into the future. 🤲🏼❤️ #ViralgenCommercial
Marianne De Backer, MSc, PhD, MBA retweeted
Thank you to our panelists from @BainCapital @pfizer @LillyPad @Bayer & @EncodedTx for a great discussion on the impact of the current #GCT M&A market on technology development. #WMIF2021
